| An SI Board Since February 1997 |
| Posts |
SubjectMarks |
Bans |
Symbol |
| 14 |
0 |
0
|
CMED |
|
CMED (NASDAQ 3.06/3.19) was the lead stock in the February issue of the MicroCapitalist Reseach Report (MCRR-FEB-2.87), which I publish. Their 2nd qtr numbers came out today and in my opinion were excellent. I have followed this company for about 3 years and they are one of the most interesting companies I have profiled in some time. The volume today was the highest since June 22nd of last year (today was approx 144k). I selected Colorado Medtech for the Feb issue because of timing- I think they are going to break out of a revenue range that has had yearly rev around the $19m-$20m area. They have moved the bottom line a long way in the past 3 years..a loss of $1m in 1993 to a profit last yr of $1.59m or 17 cents per sh. 6mo rev this year (to 12-31-96)as released today was $11.06m vs $9.1m with net inc of $945, 069 or 10 cents vs $644,238 0r 8 cents. 2nd qtr Dec was rev $5.77m vs $4.9m and net inc of $491k or 5 cents vs $335k or 4 cents.
CMED develops, manufactures and markets computerized diagnostic testing instrumentation, and together with its wholly owned subs RELA can take a concept in the front door all the way through the steps to FDA approval..including research, design, engineering, product modeling, quality assurance, and testing...and then into a production run. They are one of a very small number of companies out there that can do this...and I think they are hitting their stride....now. Next two qtrs in my opinion will be sequentially and comparitively favorable. If you want to learn more about CMED and have not yet requested a comp copy of the MCRR just drop me an email w.your mailing address on it and I will forward our Feb MCRR to you.
gary grobbel
|
|
|
